eXoZymes Inc. has priced a public offering of units to raise approximately $5.33 million in gross proceeds, aiming to fund its operations in the AI-enhanced enzyme sector. The offering consists of 296,135 units, each priced at $18.00, and includes two shares of common stock and one warrant to purchase one share of common stock. The units will separate immediately upon issuance, with shares and warrants trading as separate securities. The offering is expected to close on June 9, 2026, subject to customary closing conditions.

Offering Details

The company has sold a total of 592,270 shares of common stock and 296,135 warrants through this unit structure. The underwriter has been granted a 45-day option to purchase up to 44,420 additional units at the public offering price, less underwriting discounts and commissions, to cover over-allotments. The gross proceeds of $5.33 million are calculated before deducting underwriting discounts, commissions, and estimated offering expenses.

Securities Structure

Each unit in the offering is composed of specific equity and derivative instruments designed to provide immediate separation upon issuance. The table below outlines the composition of the units sold:

The warrants allow the holder to purchase one share of common stock. The offering provides eXoZymes with capital to advance its technologies that transform feedstock into nutraceuticals and medicines.